Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
96 hedge funds and large institutions have $279M invested in Marinus Pharmaceuticals, Inc in 2018 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 23 increasing their positions, 19 reducing their positions, and 10 closing their positions.
230% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 10
121% more call options, than puts
Call options by funds: $18.3M | Put options by funds: $8.28M
55% more capital invested
Capital invested by funds: $180M → $279M (+$99.1M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
32% more funds holding
Funds holding: 73 → 96 (+23)
21% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$12.6M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$6.4M |
| 3 |
Goldman Sachs
New York
|
+$3.37M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.91M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$2.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$11.2M |
| 2 |
Jennison Associates
New York
|
-$6.08M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$2.68M |
| 4 |
HT
HAP Trading
New York
|
-$1.55M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.27M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GCP
101
GSA Capital Partners
London,
United Kingdom
| – | -$141K | -4,975 | Closed |
|
|
FAM
102
Fred Alger Management
New York
| – | -$127K | -4,500 | Closed |
|
103
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
| – | -$120K | -4,250 | Closed |
|
|
TI
104
Trexquant Investment
Stamford,
Connecticut
| – | -$102K | -3,616 | Closed |
|
|
SO
105
STRS Ohio
Columbus,
Ohio
| – | -$76.1K | -2,675 | Closed |
|
|
PIA
106
Piedmont Investment Advisors
Durham,
North Carolina
| – | -$4K | -158 | Closed |
|
MRNS Hedge Fund Activity: Q3 2018 in Review
96 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q3 2018, worth a combined $279M — up 55% from $180M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new MRNS positions and 10 closed out — a net gain of 23 holders — while 23 added to existing stakes and 19 trimmed.
The largest buyer was PFM Health Sciences, opening a new position worth an estimated $12.6M. The largest seller was Granite Point Capital Management, cutting an estimated $11.2M.
- 96 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q3 2018, up from 73 in Q2 2018.
- Funds reported $279M of Marinus Pharmaceuticals, Inc stock for Q3 2018, up 55% quarter-over-quarter.
- 33 funds opened new Marinus Pharmaceuticals, Inc positions in Q3 2018 and 10 closed out, a net change of +23 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q3 2018 was PFM Health Sciences, an estimated $12.6M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q3 2018 was Granite Point Capital Management, an estimated $11.2M sold.
Based on aggregated 13F filings for Q3 2018.